These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 19380802

  • 1. An anti-vascular endothelial growth factor receptor 2/fetal liver kinase-1 Listeria monocytogenes anti-angiogenesis cancer vaccine for the treatment of primary and metastatic Her-2/neu+ breast tumors in a mouse model.
    Seavey MM, Maciag PC, Al-Rawi N, Sewell D, Paterson Y.
    J Immunol; 2009 May 01; 182(9):5537-46. PubMed ID: 19380802
    [Abstract] [Full Text] [Related]

  • 2. Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse.
    Singh R, Dominiecki ME, Jaffee EM, Paterson Y.
    J Immunol; 2005 Sep 15; 175(6):3663-73. PubMed ID: 16148111
    [Abstract] [Full Text] [Related]

  • 3. Targeting tumor vasculature with novel Listeria-based vaccines directed against CD105.
    Wood LM, Pan ZK, Guirnalda P, Tsai P, Seavey M, Paterson Y.
    Cancer Immunol Immunother; 2011 Jul 15; 60(7):931-42. PubMed ID: 21431419
    [Abstract] [Full Text] [Related]

  • 4. High efficacy of a Listeria-based vaccine against metastatic breast cancer reveals a dual mode of action.
    Kim SH, Castro F, Paterson Y, Gravekamp C.
    Cancer Res; 2009 Jul 15; 69(14):5860-6. PubMed ID: 19584282
    [Abstract] [Full Text] [Related]

  • 5. Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7.
    Sewell DA, Shahabi V, Gunn GR, Pan ZK, Dominiecki ME, Paterson Y.
    Cancer Res; 2004 Dec 15; 64(24):8821-5. PubMed ID: 15604239
    [Abstract] [Full Text] [Related]

  • 6. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16.
    Gunn GR, Zubair A, Peters C, Pan ZK, Wu TC, Paterson Y.
    J Immunol; 2001 Dec 01; 167(11):6471-9. PubMed ID: 11714814
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Genetic immunization of mice against Listeria monocytogenes using plasmid DNA encoding listeriolysin O.
    Cornell KA, Bouwer HG, Hinrichs DJ, Barry RA.
    J Immunol; 1999 Jul 01; 163(1):322-9. PubMed ID: 10384131
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A novel human Her-2/neu chimeric molecule expressed by Listeria monocytogenes can elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the growth and spread of Her-2/neu-positive breast tumors.
    Seavey MM, Pan ZK, Maciag PC, Wallecha A, Rivera S, Paterson Y, Shahabi V.
    Clin Cancer Res; 2009 Feb 01; 15(3):924-32. PubMed ID: 19188163
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of tumor angiogenesis in lung cancer by T4 phage surface displaying mVEGFR2 vaccine.
    Ren S, Fengyu, Zuo S, Zhao M, Wang X, Wang X, Chen Y, Wu Z, Ren Z.
    Vaccine; 2011 Aug 05; 29(34):5802-11. PubMed ID: 21482223
    [Abstract] [Full Text] [Related]

  • 12. Intracytoplasmic delivery of listeriolysin O by a vaccinal strain of Bacillus anthracis induces CD8-mediated protection against Listeria monocytogenes.
    Sirard JC, Fayolle C, de Chastellier C, Mock M, Leclerc C, Berche P.
    J Immunol; 1997 Nov 01; 159(9):4435-43. PubMed ID: 9379042
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Development of a live and highly attenuated Listeria monocytogenes-based vaccine for the treatment of Her2/neu-overexpressing cancers in human.
    Shahabi V, Seavey MM, Maciag PC, Rivera S, Wallecha A.
    Cancer Gene Ther; 2011 Jan 01; 18(1):53-62. PubMed ID: 20725099
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. FLK-1-based minigene vaccines induce T cell-mediated suppression of angiogenesis and tumor protective immunity in syngeneic BALB/c mice.
    Luo Y, Markowitz D, Xiang R, Zhou H, Reisfeld RA.
    Vaccine; 2007 Feb 09; 25(8):1409-15. PubMed ID: 17113202
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.